Abstract

Depression can be treated, and the main options are talking therapies, antidepressant medicines, or both together. Guidelines describe the choice as one made with a clinician, based on how severe the depression is, what has helped before and what the person prefers. When first treatments do not help enough, guidance describes reviewing progress, switching or adding treatments, and further options such as brain stimulation or esketamine. Self-help, exercise and lifestyle changes play a part for some people, although the evidence for several of them is weaker. Researchers still debate how much antidepressants add beyond placebo and how common and lasting withdrawal symptoms are.

Keywords: depression treatment, antidepressants, psychotherapy, treatment guidelines, treatment-resistant depression

Get Help Now

Anyone who is thinking about suicide or self-harm, or who feels unable to cope, should contact a crisis line straight away. People in immediate danger should call their local emergency number.

- United States: the 988 Suicide & Crisis Lifeline takes calls and texts at 988 (988lifeline.org). - United Kingdom: Samaritans can be called free on 116 123 (samaritans.org). - Canada: the Suicide Crisis Helpline takes calls and texts at 9-8-8 (988.ca). - Australia: Lifeline can be called on 13 11 14 (lifeline.org.au).

This guide describes what published clinical guidelines and research reviews say about treating depression. It is not a substitute for advice from a doctor or other health professional who knows a person's situation.

How Treatment Is Chosen

In England, the National Institute for Health and Care Excellence (NICE) sorts depression in adults into a less severe group and a more severe group, using a score of 16 on the PHQ-9, a short symptom questionnaire, as the dividing line (National Institute for Health and Care Excellence, 2022). NICE describes the choice as a shared decision between the person and the clinician, and it recognises the person's right to decline treatment (National Institute for Health and Care Excellence, 2022). For people whose depression is less severe and who do not want treatment, the guideline describes active monitoring, and its general approach is to use the least intrusive option that is appropriate for the person's clinical needs (National Institute for Health and Care Excellence, 2022). The Canadian guideline from the Canadian Network for Mood and Anxiety Treatments (CANMAT) also takes a personalised approach that emphasises shared decision-making (Lam et al., 2024). It names severity as a guide to the first choice, along with the person's preference, what is available and how earlier treatment went (Lam et al., 2024).

In the United States, the National Institute of Mental Health (NIMH) describes the usual options as talking therapy, medicine, or both (National Institute of Mental Health, 2024). NIMH adds that finding the best treatment may take some trial and error (National Institute of Mental Health, 2024). CANMAT reports that shared decision-making increased what people knew about their care, communication and how satisfied they were (Lam et al., 2024). It may not significantly improve symptoms or how well people stay with treatment (Lam et al., 2024).

Talking Therapies

Talking therapies, also called psychotherapy, treat depression through planned conversations with a trained therapist. NICE and the United Kingdom's National Health Service (NHS) name these main types (National Institute for Health and Care Excellence, 2022; National Health Service, 2023):

- Cognitive behavioural therapy (CBT): looks at the links between thoughts, feelings and actions. - Behavioural activation: helps a person plan and return to activities that matter to them. - Interpersonal therapy: focuses on relationships and changes in a person's life. - Counselling: offers time to talk through problems with a trained counsellor. - Short-term psychodynamic psychotherapy: explores feelings and patterns that may shape present difficulties. - Individual problem-solving: works through practical problems one step at a time.

Reviews of trials report on several of these therapies. One review pooled 26 trials with about 1,500 people and found that behavioural activation lowered depression symptoms by a large amount compared with control groups (Ekers et al., 2014). Most of the studies were of low quality, follow-up was short, and the effect shrank by 6 to 9 months (Ekers et al., 2014).

For interpersonal therapy, a review of 38 studies with about 4,400 patients found it worked better than control conditions (Cuijpers et al., 2011). It did about as well as other talking therapies, while medicine had a small advantage over interpersonal therapy alone once one outlying study was removed (Cuijpers et al., 2011).

Internet CBT delivers the same kind of therapy through an online program. Pooling individual data from 39 studies and about 9,800 people, one review found that guided internet CBT, with support from a person, did better than unguided versions at the end of treatment (Karyotaki et al., 2021). By 6 and 12 months, though, there was no evidence of a difference between the two (Karyotaki et al., 2021).

How does talking therapy compare with medicine? A network review of 101 studies with about 11,900 adults found no significant difference between them, while combining the two worked better than either one alone (Cuijpers et al., 2020). CANMAT reaches a similar view: the two work about equally in the short term, combined treatment beats either alone, and CBT did better than antidepressants at 6 to 12 months of follow-up (Lam et al., 2024).

Medicines

The NHS describes several classes, including selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs) and older tricyclic antidepressants (National Health Service, 2023). NICE lists SSRIs as the usual first choice (National Institute for Health and Care Excellence, 2022). A large review of 522 trials with about 116,500 participants compared 21 antidepressants for short-term treatment of major depression (Cipriani et al., 2018). Every one of them did better than placebo, a dummy pill; differences between the medicines were smaller when placebo-controlled trials were included and more variable in head-to-head trials, and the certainty of the evidence ranged from moderate to very low (Cipriani et al., 2018).

NIMH gives a time frame of 4 to 8 weeks (National Institute of Mental Health, 2024), while NICE expects some effect within 4 weeks (National Institute for Health and Care Excellence, 2022). NICE advises against routinely offering an antidepressant as the first treatment for less severe depression (National Institute for Health and Care Excellence, 2022). Once symptoms have gone, a state called remission, NICE says a person might stay on treatment for at least 6 months, with regular reviews along the way (National Institute for Health and Care Excellence, 2022).

NICE advises that antidepressants be reduced gradually together with the prescriber (National Institute for Health and Care Excellence, 2022). It notes that withdrawal symptoms usually go away within 1 to 2 weeks but can sometimes last longer, occasionally several months, and that they are not the same as depression coming back (National Institute for Health and Care Excellence, 2022). NIMH advises consulting a provider before stopping any medicine (National Institute of Mental Health, 2024).

NIMH notes that in some cases people under 25 may have more suicidal thoughts or behaviour when taking antidepressants, and it reports FDA advice that people of all ages be watched closely in the first few weeks of treatment (National Institute of Mental Health, 2024). NICE also describes early monitoring, because agitation and suicidal thoughts can increase at the start, and it advises a first review after 1 week for people aged 18 to 25 (National Institute for Health and Care Excellence, 2022). A pooled analysis of 24 placebo-controlled trials in about 4,600 children and teenagers found a modest rise in suicidal thinking and behaviour with antidepressants (Hammad et al., 2006). No one died by suicide in any of the trials, and only one trial on its own showed a significant effect (Hammad et al., 2006).

When First Treatments Have Not Helped

NICE advises a discussion with the person about why a treatment may not be working when the depression has shown no response at all, either after 4 weeks of taking a medicine at a recognised dose or after talking therapy lasting 4 to 6 weeks (National Institute for Health and Care Excellence, 2022). Further steps it lists include switching to another therapy or medicine, or adding exercise or a talking therapy (National Institute for Health and Care Excellence, 2022). For adding lithium or an antipsychotic medicine, NICE suggests considering referral to a specialist or consulting one (National Institute for Health and Care Excellence, 2022). In trials reviewed by CANMAT, adding a treatment did better than switching, and switching medicines was no better than staying on the same one (Lam et al., 2024).

Brain stimulation is another route. NIMH notes that it is used less often than therapy or medicine and that some types are still experimental (National Institute of Mental Health, 2024). CANMAT reports response in about 65% to 75% of people with electroconvulsive therapy (ECT) and 40% to 50% with repetitive transcranial magnetic stimulation (rTMS), where response means at least a 50% improvement (Lam et al., 2024). It rates ECT as more effective, but except in emergencies it advises that rTMS generally be considered before ECT because it is less invasive (Lam et al., 2024). A network review of 81 studies with 4,233 patients found that several forms of rTMS beat sham, a fake version of the treatment, while some newer forms did not (Brunoni et al., 2017).

NIMH describes treatment-resistant depression in terms of trying at least two antidepressants without enough benefit (National Institute of Mental Health, 2024). Esketamine, a nasal spray made from one form of the ketamine molecule, was approved by the FDA in March 2019 for adults with this kind of depression, to be started together with a standard antidepressant (McIntyre et al., 2021). It is also approved by Health Canada and the European Medicines Agency, while ketamine itself is not approved for depression (Swainson et al., 2021). CANMAT places ketamine and esketamine as second-line options and notes the practical burden of delivering them (Lam et al., 2024). For ketamine given as an infusion, reported side effects include dissociation (feeling detached from oneself), raised blood pressure, headache and nausea, which are usually mild and short-lived (Swainson et al., 2021). Long-term evidence for ketamine given into a vein is insufficient, and esketamine's benefit in adults aged 65 and over has not been established (McIntyre et al., 2021).

Self-Help, Exercise and Lifestyle

For less severe depression, NICE lists guided self-help based on CBT or behavioural activation, and group exercise programmes, among the first options (National Institute for Health and Care Excellence, 2022). Its general advice covers regular physical activity, ideally outdoors, a healthy diet, sleep and limited alcohol (National Institute for Health and Care Excellence, 2022).

NICE notes some evidence that St John's wort, a herbal remedy, may help less severe depression, but advises professionals not to prescribe it or advise its use because of uncertain doses and serious interactions with other drugs (National Institute for Health and Care Excellence, 2022), and the NHS does not recommend it either (National Health Service, 2023). CANMAT rates the evidence for exercise, complementary and alternative treatments, and guided digital treatments as weaker than for medicine and talking therapy, and suggests them on their own mainly for mild depression (Lam et al., 2024). Unlike NICE, CANMAT lists St John's wort as a first-line option for mild depression, with caution about interactions with other medicines (Lam et al., 2024).

Treatment for Young People

A review of depression in young people recommends a stepwise approach to treatment (Thapar et al., 2022). The NHS notes that SSRIs carry risks for people under 18 (National Health Service, 2023). NIMH notes that, in some cases, people under 25 may have more suicidal thoughts when taking antidepressants (National Institute of Mental Health, 2024). The NICE guideline covers adults only (National Institute for Health and Care Excellence, 2022).

What Is Still Uncertain

Researchers still disagree about how much antidepressants add beyond placebo. The Cipriani review found that every antidepressant it studied did better than placebo (Cipriani et al., 2018). An analysis of individual data from 232 trials with about 73,400 people found a small average gap between drug and placebo, about 1.75 points on the Hamilton depression scale (Stone et al., 2022). The same analysis suggested that about 15% of trial participants may gain a substantial benefit from the drug itself, with large responses more common on the drug than on placebo (Stone et al., 2022). Hengartner and Plöderl argue that the average effect falls below the lower end of estimates of the minimal important difference, the smallest change judged to matter to patients (Hengartner & Plöderl, 2022). They conclude that its clinical significance is uncertain and call for research on quality of life (Hengartner & Plöderl, 2022).

A review of 24 studies concluded that withdrawal symptoms are common, often severe and often prolonged, and argued that guidelines are out of step with the evidence on them (Davies & Read, 2019). Its studies varied widely in methods and populations (Davies & Read, 2019). A later review of 79 studies with about 21,000 patients found that symptoms after stopping were more common with antidepressants than with placebo (Henssler et al., 2024). Allowing for symptoms that also followed stopping a placebo, the authors put the rate at about 15%, roughly one in six to seven patients, although results varied a great deal (Henssler et al., 2024). CANMAT rates the evidence on how best to stop antidepressants as low certainty and finds no consensus on one method (Lam et al., 2024). CANMAT lists psilocybin as investigational, meaning still under study, with methodological limits (Lam et al., 2024).

Learn More

More detail is in the full article on depression. There are also guides to depression symptoms, major depressive disorder symptoms and treatment-resistant depression.

Frequently Asked Questions

What are the main treatments for depression?

NIMH describes the main options as talking therapy, medicine, or both. It notes that finding the right treatment may take some trial and error (National Institute of Mental Health, 2024).

How long do antidepressants take to work?

NIMH says antidepressants usually take 4 to 8 weeks to work. It adds that sleep, appetite and concentration often get better before mood does (National Institute of Mental Health, 2024).

Is talking therapy as effective as medicine?

A large network review found no significant difference between talking therapy and medicine. Combining the two worked better than either alone (Cuijpers et al., 2020).

Can a person stop antidepressants suddenly?

NICE advises that antidepressants be reduced gradually with the prescriber. It notes that withdrawal symptoms usually clear within 1 to 2 weeks, but can sometimes last several weeks or months and can be severe, particularly if the medicine is stopped suddenly (National Institute for Health and Care Excellence, 2022).

What happens if the first treatment does not help?

NICE describes reviewing progress and then switching to another therapy or medicine, or adding exercise or a talking therapy. For combinations of medicines, it advises considering referral to a specialist or consulting one (National Institute for Health and Care Excellence, 2022).

Do natural remedies such as St John's wort help?

NIMH notes that findings on natural products are inconsistent, that none is FDA-approved and that supplements can interact with medicines (National Institute of Mental Health, 2024).

How This Article Was Prepared

This is a plain-language patient guide, not a systematic review. Following medical sourcing guidance, it rests on secondary sources rather than single studies: two clinical guidelines, 14 reviews of the research and two pages from public health agencies.

- Included: 18 sources, each confirmed against the publisher's or indexer's own record. Eight read in full text and 10 from their abstracts. Agency and guideline pages were read on the publisher's own site. Abstracts came from PubMed and Crossref. - Identifiers: 15 references carry a PubMed ID and nine a PubMed Central ID, each confirmed by the National Library of Medicine against the cited DOI. - Retractions: 15 sources were checked for retractions and editorial notices; none was retracted. - Publication dates: one from the 2000s, five from the 2010s and 12 from 2020 or later. - Checked against sources: each of the 72 cited sentences was matched to a passage in its source, and an independent reviewer checked the article against those sources over seven passes before publication. - Limits: a short guide summarises selected sources and cannot cover every symptom or situation; it is not a diagnosis or a substitute for seeing a health professional. Each sentence was accepted only after its cited source had been searched for contrary evidence.

See our Editorial Policy for the full method.

References

Brunoni, A. R., Chaimani, A., Moffa, A. H., Razza, L. B., Gattaz, W. F., Daskalakis, Z. J., & Carvalho, A. F. (2017). Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: A systematic review with network meta-analysis. JAMA Psychiatry, 74(2), 143-152. https://doi.org/10.1001/jamapsychiatry.2016.3644 PMID: 28030740

Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7 PMID: 29477251 · PMCID: PMC5889788

Cuijpers, P., Geraedts, A. S., van Oppen, P., Andersson, G., Markowitz, J. C., & van Straten, A. (2011). Interpersonal psychotherapy for depression: A meta-analysis. American Journal of Psychiatry, 168(6), 581-592. https://doi.org/10.1176/appi.ajp.2010.10101411 PMID: 21362740 · PMCID: PMC3646065

Cuijpers, P., Noma, H., Karyotaki, E., Vinkers, C. H., Cipriani, A., & Furukawa, T. A. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry, 19(1), 92-107. https://doi.org/10.1002/wps.20701 PMID: 31922679 · PMCID: PMC6953550

Davies, J., & Read, J. (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addictive Behaviors, 97, 111-121. https://doi.org/10.1016/j.addbeh.2018.08.027 PMID: 30292574

Ekers, D., Webster, L., Van Straten, A., Cuijpers, P., Richards, D., & Gilbody, S. (2014). Behavioural activation for depression; an update of meta-analysis of effectiveness and sub group analysis. PLoS ONE, 9(6), e100100. https://doi.org/10.1371/journal.pone.0100100 PMID: 24936656 · PMCID: PMC4061095

Hammad, T. A., Laughren, T., & Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63(3), 332-339. https://doi.org/10.1001/archpsyc.63.3.332 PMID: 16520440

Hengartner, M. P., & Plöderl, M. (2022). Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evidence-Based Medicine, 27(2), 69-73. https://doi.org/10.1136/bmjebm-2020-111600 PMID: 33593736

Henssler, J., Schmidt, Y., Schmidt, U., Schwarzer, G., Bschor, T., & Baethge, C. (2024). Incidence of antidepressant discontinuation symptoms: A systematic review and meta-analysis. The Lancet Psychiatry, 11(7), 526-535. https://doi.org/10.1016/S2215-0366(24)00133-0 PMID: 38851198

Karyotaki, E., Efthimiou, O., Miguel, C., Bermpohl, F. M. G., Furukawa, T. A., Cuijpers, P., & Individual Patient Data Meta-Analyses for Depression (IPDMA-DE) Collaboration. (2021). Internet-based cognitive behavioral therapy for depression: A systematic review and individual patient data network meta-analysis. JAMA Psychiatry, 78(4), 361-371. https://doi.org/10.1001/jamapsychiatry.2020.4364 PMID: 33471111 · PMCID: PMC8027916

Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., Blier, P., Blumberger, D. M., Brietzke, E., Chakrabarty, T., Do, A., Frey, B. N., Giacobbe, P., Gratzer, D., Grigoriadis, S., Habert, J., Husain, M. I., Ismail, Z., McGirr, A., . . . Milev, R. V. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. The Canadian Journal of Psychiatry, 69(9), 641-687. https://doi.org/10.1177/07067437241245384 PMID: 38711351 · PMCID: PMC11351064

McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D. V., Lopez Jaramillo, C., Kasper, S., Kratiuk, K., Lee, J. G., Lee, Y., Lui, L. M. W., Mansur, R. B., Papakostas, G. I., Subramaniapillai, M., Thase, M., Vieta, E., Young, A. H., Zarate, C. A., Jr., & Stahl, S. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry, 178(5), 383-399. https://doi.org/10.1176/appi.ajp.2020.20081251 PMID: 33726522 · PMCID: PMC9635017

National Health Service. (2023, July 5). Treatment - Depression in adults. NHS. https://www.nhs.uk/mental-health/conditions/depression-in-adults/treatment/

National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NICE guideline NG222). https://www.nice.org.uk/guidance/ng222/chapter/Recommendations

National Institute of Mental Health. (2024). Depression (NIH Publication No. 24-MH-8079). U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/publications/depression

Stone, M. B., Yaseen, Z. S., Miller, B. J., Richardville, K., Kalaria, S. N., & Kirsch, I. (2022). Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: Individual participant data analysis. BMJ, 378, e067606. https://doi.org/10.1136/bmj-2021-067606 PMID: 35918097 · PMCID: PMC9344377

Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., McIntyre, R. S., Milev, R. V., Parikh, S. V., Schaffer, A., Taylor, V. H., Tourjman, V., van Ameringen, M., Yatham, L. N., Ravindran, A. V., & Lam, R. W. (2021). The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the use of racemic ketamine in adults with major depressive disorder. The Canadian Journal of Psychiatry, 66(2), 113-125. https://doi.org/10.1177/0706743720970860 PMID: 33174760 · PMCID: PMC7918868

Thapar, A., Eyre, O., Patel, V., & Brent, D. (2022). Depression in young people. The Lancet, 400(10352), 617-631. https://doi.org/10.1016/S0140-6736(22)01012-1 PMID: 35940184